IPCA Laboratories Ltd. saw a 2% rise in its stock price following impressive Q2 results for the September quarter.
The company reported a 58% year-on-year increase in net profit, reaching ₹229.48 crore, up from ₹145.06 crore in the same period last year. Revenue from operations grew by 16%, totaling ₹2,354.90 crore compared to ₹2,033.95 crore in Q2 2023.
EBITDA surged 22.5%, standing at ₹441.7 crore, with margins expanding by 110 basis points to 18.8%. The robust earnings performance has boosted investor confidence in the company’s outlook.
As of 2:07 pm, IPCA Laboratories shares were trading 1.94% higher at Rs 1,534.10 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
